Compare UFG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | EVAX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Singapore | Denmark |
| Employees | 26 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 23.6M |
| IPO Year | N/A | 2020 |
| Metric | UFG | EVAX |
|---|---|---|
| Price | $0.45 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 59.7K | 12.0K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $2.52 |
| 52 Week High | $9.91 | $12.15 |
| Indicator | UFG | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 19.87 | 46.42 |
| Support Level | N/A | $2.97 |
| Resistance Level | $1.02 | $3.61 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 2.77 | 59.21 |
Uni-Fuels Holdings Ltd is a service provider of marine fuel solutions. It operates on an integrated business model, serving customers through two operating models: sales of marine fuels solutions and brokerage (i.e., acting as an intermediary between marine fuels suppliers and customers for a commission). The various marine fuel products offered by the company include very low sulfur fuel oil, high sulfur fuel oil, marine gas oil, and bio marine fuel. Its customers are mainly shipping companies and other fuel suppliers operating in market sectors such as bulk, tanker, offshore, container, general cargo, tug and barge, car carrier, cruise, yacht, and dredging. Geographically, the company derives maximum revenue from Singapore, and the rest from Malaysia, Hong Kong, China, and other regions.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.